Alexa Fluor® 555 Anti-SLFN12 antibody [EPR20904-32]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

SLFN12 also known as Schlafen family member 12 is a protein that plays a role in protein synthesis regulation and innate immunity. It carries a mass of approximately 65 kDa. The protein shows expression in multiple human tissues including the colon small intestine and prostate. SLFN12 contains a notable AAA+ ATPase domain which suggests involvement in processes requiring energy such as molecular chaperone activity. Researchers have studied its expression pattern noting its presence at the cellular level which hints at diverse functional implications across various cells.

Biological function summary

SLFN12 modulates the differentiation of cells and appears to play a role in immune response. It does not form part of a large protein complex. It functions independently to exert effects specifically influencing maturation of specific immune cells and contributing to maintaining cellular homeostasis. Its role in differentiation makes it significant in balancing immune responses ensuring cells reach necessary maturity to perform their function in defense mechanisms.

Pathways

Studies highlight that SLFN12 contributes to the regulation of protein synthesis and the immune response pathway. In the synthesis pathway it potentially interacts with ribosomal proteins to regulate production of proteins modulating cell homoeostasis and growth. Meanwhile its involvement in the immune response pathway shows interaction with other SLFN family proteins altering cellular responses to microbial infections. Research also suggests it operates alongside proteins like SLFN11 to ensure effective cellular defense against pathogenic attacks.

Associated diseases and disorders

Researchers have associated SLFN12 with inflammatory bowel disease and certain types of cancer such as prostate cancer. Its expression patterns in inflamed tissue suggest that SLFN12 may mediate inflammatory responses exacerbating or alleviating the condition. In prostate cancer SLFN12 seems to interact with the androgen receptor pathway potentially influencing cancer cell proliferation. Understanding these interactions and their pathological consequences will provide insights into its role in disease mechanisms and offer perspectives for therapeutics targeting SLFN12-mediated pathways.